

FOR RELEASE, February 12, 2009

Trinity Biotech Announces Appointment of James D. Merselis as a Non-Executive Director

DUBLIN, Ireland (Feb 12, 2009) -- Trinity Biotech plc (Nasdaq: [TRIB](#)), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced it has appointed James D. Merselis to its Board as a non-executive director.

Mr. Merselis is currently President and CEO of Alverix, Inc., a privately held optoelectronics company developing portable medical diagnostic instruments in cooperation with leading point-of-care (POC) diagnostics companies.

Most recently, Mr. Merselis served as President and CEO of HemoSense, Inc. (AMEX: HEM), a point-of-care diagnostics company focused initially on providing patients and physicians with rapid test results to help manage the risk of stroke with the drug warfarin or Coumadin. HemoSense was acquired by Inverness Medical Innovations, Inc. (AMEX: IMA) in late 2007 for \$265 million. Prior to his tenure at HemoSense, Merselis served as President and CEO of Micronics, Inc., a microfluidics company that develops near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. In addition, he held a number of positions over twenty-two years with Boehringer Mannheim Diagnostics (now Roche Diagnostics).

The appointment of Mr. Merselis brings the number of Directors on the Board of Trinity Biotech to seven in total, of which five are non-executive members.

Commenting on the appointment, Ronan O'Caoimh, Chairman and CEO, said, "Trinity is delighted to have the benefit of Jim's extensive industry experience, particularly in the areas of point-of-care, haemostasis and infectious diseases and he will make a very welcome addition to our Board."

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Contact : **Trinity Biotech plc**

Niamh Long
(353)-1-2769800
E-mail: niamh.long@trinitybiotech.com

Lytham Partners LLC

Joe Diaz, Joe Dorame & Robert Blum
602-889-9700